Adoption and de-adoption of drotrecogin alfa for severe sepsis in the United States

Journal of Critical Care
Jeremy M Kahn, Tri Q Le

Abstract

Drotrecogin alfa was a landmark drug for treatment of severe sepsis, yet little is known about how it was adopted and de-adopted during its 10-year period of availability. We used hospitalization data on fee-for-service Medicare beneficiaries from 2002 to 2011 to characterize trends in the use of drotrecogin alfa in the United States. Drotrecogin alfa use peaked at 5.87 per 1000 severe sepsis hospitalizations in 2003 and then steadily declined to 0.94 administrations per 1000 severe sepsis hospitalizations in 2010. Large teaching hospitals were more likely to use drotrecogin alfa than small, nonteaching hospitals. The addition of "add-on payments" to hospitals for using drotrecogin alfa in 2002 was associated with significantly increased use (P < .0001), and the withdrawal of those payments in 2004 was associated significantly decreased use (P < .0001). Neither the publication of international sepsis guidelines with favorable drotrecogin alfa recommendations (in 2004 and 2008) nor the publication of a clinical trial focused on drotrecogin alfa (in 2005) were associated with consistent changes use (P > .05). Drotrecogin alfa use declined over time, with marked changes in use associated with drug-specific financial incentives but...Continue Reading

References

Oct 27, 1999·JAMA : the Journal of the American Medical Association·M D CabanaH R Rubin
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
Mar 5, 2004·Intensive Care Medicine·R Phillip DellingerM M Levy
Jun 11, 2004·Chest·Gordon R BernardUNKNOWN Extended Evaluation of Recombinant Human Activated Protein C United States Investigators
Jul 24, 2004·American Journal of Respiratory and Critical Care Medicine·Theodore J Iwashyna
Sep 30, 2005·The New England Journal of Medicine·Edward AbrahamUNKNOWN Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group
Jul 27, 2007·JAMA : the Journal of the American Medical Association·Renda Soylemez Wiener, H Gilbert Welch
Oct 27, 2007·American Journal of Respiratory and Critical Care Medicine·Andrés EstebanUNKNOWN VENTILA Group
Dec 7, 2007·Intensive Care Medicine·R Phillip DellingerJean-Louis Vincent
Dec 26, 2007·Critical Care Medicine·R Phillip DellingerUNKNOWN World Federation of Societies of Intensive and Critical Care Medicine
Nov 11, 2008·Health Affairs·Alexandra T ClydeChristine Jackson
Jan 6, 2009·Critical Care Medicine·Jeremy M Kahn
Mar 26, 2010·American Journal of Respiratory and Critical Care Medicine·Jeremy M KahnUNKNOWN American Thoracic Society Pay-for-Performance Working Group
Jan 21, 2011·JAMA : the Journal of the American Medical Association·Damon C ScalesMerrick Zwarenstein
Feb 18, 2012·Critical Care Medicine·Martin D BlackMitchell M Levy
May 24, 2012·The New England Journal of Medicine·V Marco RanieriUNKNOWN PROWESS-SHOCK Study Group
May 31, 2012·Journal of the American Geriatrics Society·Theodore J IwashynaJeremy M Kahn
Mar 21, 2013·Critical Care : the Official Journal of the Critical Care Forum·Andre L Holder, David T Huang
Aug 14, 2013·Critical Care Medicine·Tasnim SinuffUNKNOWN KRITICAL Working Group, the Canadian Critical Care Trials Group, and the Canadian Critical Care Society
Aug 28, 2013·Critical Care Medicine·Hayley B Gershengorn, Hannah Wunsch
Mar 17, 2015·JAMA Internal Medicine·Daniel J NivenHenry T Stelfox

❮ Previous
Next ❯

Citations

Feb 3, 2016·Journal of Critical Care·Bruce Gingles
Oct 16, 2016·Annals of the American Thoracic Society·Laveena MunshiGordon D Rubenfeld
Jul 31, 2019·Current Opinion in Critical Care·Christopher M Fung, Robert C Hyzy
Aug 10, 2019·Intensive Care Medicine·Henry T StelfoxDaniel J Niven
Jun 19, 2019·BMJ : British Medical Journal·Timothy J JudsonRita F Redberg
Mar 28, 2019·Annals of the American Thoracic Society·Alexander S NivenOgnjen Gajic

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The International Journal of Artificial Organs
William L MaciasB W Grinnell
The New England Journal of Medicine
Steven P LaRosa
The New England Journal of Medicine
J K Baillie, G Murray
© 2022 Meta ULC. All rights reserved